A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight

NCT06207877 · Completed

Last updated 2026-05-28

This study tests how the medication CagriSema affects hunger, appetite, and digestion in adults who have excess body weight.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 62 people

Who can join Ages 18–65 · all sexes

Timeline Started 2024-02 · est. completion 2024-11

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT06207877 ↗

Description as written by the study sponsor.

This research study tests if CagriSema influences food intake, appetite and emptying of the stomach in people with excess body weight. Participant will either get CagriSema (active medicine) or placebo (a dummy medicine), which has no effect on the body. The treatment participants get is decided by chance. The study will last for about 32 weeks.

Treatments tested

Cagrilintide Drug

Cagrilintide will be administered subcutaneously.
Semaglutide Drug

Semaglutide will be administered subcutaneously.
Placebo Drug

Placebo will be administered subcutaneously.

Main thing measured	Relative change in energy intake during ad libitum lunch, evening meal and snackbox
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06207877 ↗